Praxis Precision Medicines

Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.

Funding reportedLast round: Post-IPO Equity

Alternative MedicineCambridge, United States

What company datasets say Praxis Precision Medicines raised

Funding, as reported

Reported in all$575Min dollars

Last roundPost-IPO Equity

Investors listed5

SEC Form D$32M sold, 3 filings, last Jun 2019

From Praxis Precision Medicines's own website and the SEC filings it signed: 1 founder, 18 on the team.

Steve PetrouCo-Founder, President of Research & Development

On the board, as filediAlfred SandrockAri BrettmanGregory NordenNicholas GalakatosPaul MedeirosStefan VitorovicThomas Dyrberg

AdvisersMatt Might

Investors who name them

Each firm lists Praxis Precision Medicines on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put Praxis Precision Medicines in front of investors. Or tell us what we have wrong.